Literature DB >> 25719977

Lipid profile and statin use: the paradox of survival after acute exacerbation of chronic obstructive pulmonary disease.

Oren Fruchter1, Mordechai Yigla, Mordechai R Kramer.   

Abstract

BACKGROUND: A paradoxical association between cholesterol level and clinical outcome has been suggested, yet never previously established, in patients with chronic obstructive pulmonary disease (COPD).
OBJECTIVES: The authors sought to investigate the interaction between long-term survival, lipid profile and statin use in patients after acute exacerbation of COPD (AECOPD).
METHODS: A retrospective study evaluating demographic, clinical and laboratory data of 615 consecutive patients admitted for AECOPD over a mean follow-up period of 24.8 months. Kaplan-Meier survival curves and multivariate analysis were used to identify independent prognostic predictors for all-cause mortality.
RESULTS: Mean ± standard deviation (SD) age of the study population was 71.8 ± 11.4 years. Unexpectedly, mean serum cholesterol ± SD levels were significantly higher in survivors (N = 340) versus nonsurvivors (N = 275): 181.5 ± 43.6 versus 171.6 ± 57.2 mg/dL, respectively, (P = 0.0043). Median survival for patients with cholesterol levels <150 and >200 mg/dL were 16.0 and 64.4 months, respectively (P = 0.0173). On multivariate analysis, cholesterol level <150 mg/dL was an independent predictor of mortality, irrespective of cardiovascular risk factors (hazard ratio [HR] = 1.8430, 95% confidence interval [CI] = 1.2547-2.7072, P = 0.0019). Statin use had an independent protective effect, regardless of cholesterol level (HR = 0.4924, 95% CI = 0.2924-0.8292, P = 0.0080).
CONCLUSIONS: Low cholesterol levels are significantly associated with increased mortality after AECOPD. Nonetheless, as statin treatment was associated with reduced mortality over the entire range of cholesterol levels, its use should be considered in all COPD patients.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25719977     DOI: 10.1097/MAJ.0000000000000435

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  4 in total

1.  Acute and chronic effects of treatment with mesenchymal stromal cells on LPS-induced pulmonary inflammation, emphysema and atherosclerosis development.

Authors:  P Padmini S J Khedoe; Stan de Kleijn; Annemarie M van Oeveren-Rietdijk; Jaap J Plomp; Hetty C de Boer; Melissa van Pel; Patrick C N Rensen; Jimmy F P Berbée; Pieter S Hiemstra
Journal:  PLoS One       Date:  2017-09-14       Impact factor: 3.240

2.  The "cholesterol paradox" among inpatients - retrospective analysis of medical documentation.

Authors:  Jacek Budzyński; Krzysztof Tojek; Beata Wustrau; Beata Czerniak; Piotr Winiarski; Wanda Korzycka-Wilińska; Zbigniew Banaszkiewicz
Journal:  Arch Med Sci Atheroscler Dis       Date:  2018-03-27

3.  Downregulated level of insulin in COPD patients during AE; role beyond glucose control?

Authors:  Wenjing Ruan; Chao Yan; Huiqi Zhu; Shuwen Wang; Xuan Jia; Lingyan Shao; Zhihao Xu; Kejing Ying
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-07-15

4.  Statins reduce all-cause mortality in chronic obstructive pulmonary disease: an updated systematic review and meta-analysis of observational studies.

Authors:  Wen-Feng Li; Yu-Qing Huang; Cheng Huang; Ying-Qing Feng
Journal:  Oncotarget       Date:  2017-08-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.